EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Uric Acid, the End-Product of Purine Metabolism, Mitigates Tau-Related Abnormalities: Comparison with DOT, a Non-Antibiotic Oxytetracycline Derivative

Bianca Andretto de Mattos iD, Rodrigo Hernán Tomas-Grau iD, Thaís Antonia Alves Fernandes iD, Florencia González-Lizárraga, Aurore Tourville iD, Ismaila Ciss, Jean-Michel Brunel iD, Rosana Chehin iD, Annie Lannuzel, Laurent Ferrié iD, Rita Raisman-Vozari, Bruno Figadère iD und 2 weitere

Biomolecules · 28.06.2025 · 15 (7) · 941

DOI: 10.3390/biom15070941 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Biomolecules, online erschienen am 28.06.2025. Verfasst von Bianca Andretto de Mattos und 13 weiteren Autor:innen. Beteiligte Einrichtung: Paris Brain Institute-ICM, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Sorbonne Université, 75013 Paris, France. Hauptthemen laut MEDLINE: Uric Acid, tau Proteins, Purines, Tauopathies. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation Recherche Alzheimer, Institut Carnot, Capes-Cofecub.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We aimed to simulate tau abnormalities—specifically hyperphosphorylation and aggregation—that are hallmarks of tauopathies, including Alzheimer’s disease, to evaluate tau-targeting therapies. To model pathological p-tau accumulation at early disease stages, we exposed mouse cortical cultures to redox-active iron from hemin (Hm), a breakdown product of hemoglobin, or challenged them with the excitatory neurotransmitter glutamate. Using the AT8 phospho-specific antibody, we demonstrate that a subtoxic concentration of Hm (3 µM) promotes pathological p-tau accumulation in a subpopulation of cultured cortical neurons and their proximal neurites. Uric acid (UA; 0.1–200 µM), the metabolic end-product of purines in humans, prevented p-tau build-up. Neither xanthine, the immediate precursor of UA, nor allantoin, its oxidized product, reproduced this effect. Live cell imaging studies revealed that UA operates by repressing iron-driven lipid peroxidation. DOT (3 µM), a brain-permeant tetracycline (TC) without antibiotic activity, mimicked UA’s anti-tau and antioxidant effects. Interestingly, both UA and DOT remained effective in preventing p-tau accumulation induced by glutamate (10 µM). To simulate tau aggregation at more advanced disease stages, we conducted a Thioflavin-T aggregation assay. Our findings revealed that UA and DOT prevented tau aggregation seeded by heparin. However, only DOT remained effective when heparin-assembled tau fibrils were used as the seeding material. In summary, our results indicate that UA-elevating agents may hold therapeutic utility for tauopathies. The non-purine compound DOT could serve as an effective alternative to UA-related therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uric Acidtau ProteinsPurinesTauopathiesAnimalsMiceNeuronsHumansCells, CulturedPhosphorylation

Stichwörter der Autor:innen

Alzheimer diseaseaggregationexcitotoxicityheminironnon-antibiotic tetracyclinesoxidative stressphospho-tautauopathies

Substanzen

Uric Acidtau ProteinsPurinespurine

Autor:innen und Institutionen

  • Paris Brain Institute-ICM, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Sorbonne Université, 75013 Paris, France.
  • Medical School of Ribeirão Preto, Department of Physiology, University of Sao Paulo, Ribeirão Preto 14040-904, Brazil.
  • IMMCA, CONICET-UNT-SIPROSA, Tucumán 4000, Argentina.
  • BioCIS, CNRS, Université Paris-Saclay, 91400 Orsay, France.
  • Inserm, Membranes et Cibles Thérapeutiques, Service de Santé des Armées, Aix Marseille Université, 13385 Marseille, France.
  • Department of Neurology, CIC1424, University Hospital of Guadeloupe, Antilles University, French West Indies, 97159 Pointe-à-Pitre, France.

ORCID-Profile: Bianca Andretto de Mattos, Rodrigo Hernán Tomas-Grau, Thaís Antonia Alves Fernandes, Aurore Tourville, Jean-Michel Brunel, Rosana Chehin, Laurent Ferrié, Bruno Figadère, Patrick Pierre Michel

Förderung

  • Fondation Recherche Alzheimer
  • Institut Carnot
  • Capes-Cofecub
  • Capes
  • Ministerio de Ciencia, Tecnología e Innovación
  • National University of Tucumán
  • Program Investissements d'Avenir
  • Translational Research Infrastructure for Biotherapies in Neurosciences

Zitieren

APA

Andretto de Mattos, B., Tomas-Grau, R. H., Alves Fernandes, T. A., González-Lizárraga, F., Tourville, A., Ciss, I., Brunel, J. M., Chehin, R., Lannuzel, A., Ferrié, L., Raisman-Vozari, R., Figadère, B., Del Bel, E., & Michel, P. P. (2025). Uric Acid, the End-Product of Purine Metabolism, Mitigates Tau-Related Abnormalities: Comparison with DOT, a Non-Antibiotic Oxytetracycline Derivative. Biomolecules, 15(7), 941. https://doi.org/10.3390/biom15070941

Vancouver

Andretto de Mattos B, Tomas-Grau RH, Alves Fernandes TA, González-Lizárraga F, Tourville A, Ciss I, et al. Uric Acid, the End-Product of Purine Metabolism, Mitigates Tau-Related Abnormalities: Comparison with DOT, a Non-Antibiotic Oxytetracycline Derivative. Biomolecules. 2025;15(7):941. doi:10.3390/biom15070941

BibTeX
@article{AndrettodeMattos2025,
  author = {Andretto de Mattos, Bianca and Tomas-Grau, Rodrigo Hernán and Alves Fernandes, Thaís Antonia and González-Lizárraga, Florencia and Tourville, Aurore and Ciss, Ismaila and Brunel, Jean-Michel and Chehin, Rosana and Lannuzel, Annie and Ferrié, Laurent and Raisman-Vozari, Rita and Figadère, Bruno and Del Bel, Elaine and Michel, Patrick Pierre},
  title = {Uric Acid, the End-Product of Purine Metabolism, Mitigates Tau-Related Abnormalities: Comparison with DOT, a Non-Antibiotic Oxytetracycline Derivative},
  journal = {Biomolecules},
  year = {2025},
  volume = {15},
  number = {7},
  pages = {941},
  doi = {10.3390/biom15070941}
}
Kostenlos starten →